The global therapeutics market for Irritable Bowel Syndrome is set to rise in value from $589.6 million in 2013 to $1.5 billion by 2023, representing a high compound annual growth rate of almost 9.9%, according to a report published Thursday by research and consulting firm GlobalData.
With specialty and biotech drugs claiming an ever-greater share of the pharmaceutical market and spawning a backlash from payers and patients over their high price tags, pharmacy operators are smack in the middle of a growing tug of war between the drug industry, the public and private health plans struggling to keep up with the new drug-cost paradigm.
Boehringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva Respimat (tiotropium bromide) inhalation spray is now available by prescription through pharmacies across the United States.
Teva Pharmaceutical on Tuesday announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA vs. Sandoz et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for Copaxone (glatiramer acetate injection) 20 mg/mL.
The Food and Drug Administration has expanded the age indication for Natroba (spinosad) topical suspension 0.9% to include children 6 months of age and older who have head lice infestations (pediculosis capitis).
AbbVie announced that the Food and Drug Administration has approved its Duopa (carbidopa and levodopa) enteral suspension, which is used to treat motor fluctuations for people with advanced Parkinson's disease.
A report published in the Jan. 16 Morbidity and Mortality Weekly Report estimates that getting a flu vaccine this season reduced a person’s risk of having to go to the doctor because of flu by 23% among people of all ages.